Chromogenic Multiplex Biomarker Profiling of Human FFPE Tissues Using UltraPlex Technology

Helen Snyder, PhD, Director of Preclinical Development and Strategic Partnerships Cell IDx

RELATED PRODUCTS
RELATED TAGS AND TOPICS
Automated IHC Workflow, Multiplex, Chromogenic Staining, Biomarkers
SHARE

Cell IDx’s UltraPlex chromogenic multiplex IHC technology allows the chromogenic detection of 3-4 markers simultaneously on a single tissue section using standard industry workflows. The protocol has been developed to run on the BOND RX autostainer using a single antigen retrieval step and is completed in ~4.5 hours. Adding to its broad utility, BOND RX the technology is primary antibody species independent. Images are obtained on all brightfield scanners in 5-15 minutes. This tissue conserving technology provides maximal information on small tissue samples. FFPE tissue-optimized panels for key biomarkers are available and other panels can be developed on request.

 

Learning Objectives

  • Learn how UltraPlex chromogenic multiplex  IHC  technology allows detection of multiple cell subtypes co-expressing multiple biomarkers using optimized chromogen combinations.
  • Learn how to expedite your data generation using a simple, fast, streamlined process combining UltraPlex chromogenic multiplex  IHC  panels with staining on the BOND RX staining platform and Aperio brightfield scanners.
  • Learn how to increase data generation from limited FFPE tissue samples including TMAs using this tissue conserving technology.

El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.

Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.

Copyright © 2022 Leica Biosystems division of Leica Microsystems, Inc. y sus filiales de Leica Biosystems. Todos los derechos reservados. LEICA y el logotipo de Leica son marcas comerciales registradas de Leica Microsystems IR GmbH.

About the presenter

Helen Snyder, PhD, Director of Preclinical Development and Strategic Partnerships Cell IDx

Received her PhD in immunology from the University of Cambridge, UK and trained as a postdoctoral fellow at Scripps Research Institute, La Jolla, California. Dr. Snyder has over 30 years' experience in immunology research, reagent development, preclinical development of biotherapeutics, and business development of immunoassay and immunodiagnostic products. She has held positions as Associate Professor at the University of California, San Diego, as well as Director of Immunology at Dynavax Technologies and key business development roles at both Solulink Biosciences and Cell IDx. Dr Snyder has over 40 papers and reviews in the areas of immune regulation and vaccine development and holds two patents.